<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Clotting factor concentrates used in the treatment of haemophilia are now procured centrally in the UK by nationally organised competitive tendering to obtain the best product price while still preserving some degree of prescribing freedom. Inevitably, however, some patients are required to switch from one brand of factor VIII to another to fulfil contractual requirements. This process of switching patients from one product to another falls to staff at individual haemophilia centres, with haemophilia nurses in particular playing a key role. This article outlines the national procurement process and discusses how the switch can be managed quickly and smoothly, as well as providing practical guidance on selecting which patients may be asked to switch. Issues such as patient communication, managing potential patient anxiety and efficient stock management are also discussed.</p></abstract>

Clotting factor concentrates used in the treatment of haemophilia are now procured centrally in the UK by nationally organised competitive tendering to obtain the best product price while still preserving some degree of prescribing freedom. Inevitably, however, some patients are required to switch from one brand of factor VIII to another to fulfil contractual requirements. This process of switching patients from one product to another falls to staff at individual haemophilia centres, with haemophilia nurses in particular playing a key role. This article outlines the national procurement process and discusses how the switch can be managed quickly and smoothly, as well as providing practical guidance on selecting which patients may be asked to switch. Issues such as patient communication, managing potential patient anxiety and efficient stock management are also discussed.

Switching factor products: selecting patients and managing the process

The Journal of Haemophilia Practice

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Switching factor products: selecting patients and managing the process"}

Clotting factor concentrates used in the treatment of haemophilia are now procured centrally in the UK by nationally organised competitive tendering to obtain...

Switching factor products: selecting patients and managing the process

Article Category: Policy and Practice

Data publikacji: 21 kwi 2018

Zakres stron: 24 - 29

DOI: https://doi.org/10.17225/jhp.00021

Słowa kluczowe
haemophilia, national tender, switching, factor VIII

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Switching factor products: selecting patients and managing the process

Article Category: Policy and Practice

Data publikacji: 21 kwi 2018

Zakres stron: 24 - 29

DOI: https://doi.org/10.17225/jhp.00021

Słowa kluczowehaemophilia, national tender, switching, factor VIII

© 2018

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Słowa kluczowe
haemophilia, national tender, switching, factor VIII